Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122906343 | 12290634 | 3 | F | 20151105 | 20160617 | 20160421 | 20160720 | EXP | PHHY2016KR053486 | NOVARTIS | 52.25 | YR | F | Y | 0.00000 | 20160720 | MD | KR | KR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122906343 | 12290634 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 35400 | MG | U | 22068 | 600 | MG | CAPSULE | QD | |||
| 122906343 | 12290634 | 2 | SS | TASIGNA | NILOTINIB | 1 | Oral | 400 MG, QD | 35400 | MG | U | 22068 | 400 | MG | CAPSULE | QD | |||
| 122906343 | 12290634 | 3 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Intravenous (not otherwise specified) | 200 MG, UNK | 0 | 200 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122906343 | 12290634 | 1 | Chronic myeloid leukaemia |
| 122906343 | 12290634 | 3 | Prophylaxis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122906343 | 12290634 | Headache |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122906343 | 12290634 | 1 | 20150908 | 20151105 | 0 | |
| 122906343 | 12290634 | 2 | 20151215 | 0 | ||
| 122906343 | 12290634 | 3 | 20151210 | 20151210 | 0 |